Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters











Database
Language
Publication year range
1.
Ann Hepatol ; 1(2): 56-63, 2002.
Article in English | MEDLINE | ID: mdl-15115969

ABSTRACT

Viremia shows only minor fluctuations in untreated patients chronically infected with hepatitis C virus. The steady state situation of balanced viral production and clearance in untreated patients can be disturbed by active antiviral treatment. After initiating interferon- alpha therapy, a typical biphasic decline of viremia can be observed and analyzed. Evaluation of mathematical models of viral dynamics during the initial phase of antiviral treatment shows high turnover rates of pre-treatment viral production and clearance of about 10(11) -10(13) virions each day and in-vivo half-lives of a few hours for free hepatitis C virions. During the first 24 to 48 hours of therapy, a dose-dependent first phase of interferon-alpha induced viral kinetics is characterized by a rapid exponential decline of serum viral load. Then viral decline enters a second phase of a relatively slow exponential decay during the following weeks of therapy which mainly reflects the death rate of infected hepatocytes. This second phase decay is predictive for the virologic end-of-treatment and even more the sustained response. Non-responding patients typically show constant viremia or even a rebound during this second phase.


Subject(s)
Antiviral Agents/therapeutic use , Hepacivirus/metabolism , Hepatitis C, Chronic/virology , Interferon-alpha/therapeutic use , Polyethylene Glycols/therapeutic use , RNA, Viral/blood , Ribavirin/therapeutic use , Viremia/drug therapy , Antiviral Agents/pharmacokinetics , Dose-Response Relationship, Drug , Drug Synergism , Drug Therapy, Combination , Hepacivirus/genetics , Hepatitis C, Chronic/drug therapy , Hepatitis C, Chronic/metabolism , Humans , Interferon alpha-2 , Interferon-alpha/pharmacokinetics , Models, Theoretical , Polyethylene Glycols/pharmacokinetics , RNA, Viral/genetics , Recombinant Proteins , Ribavirin/pharmacokinetics , Viral Load , Viremia/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL